Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review

Clinical Drug Investigation

Volumn 36, Issue 6, 2016, Pages 433-441

  Guo, Xia ^a   Yang, Qing ^b   Dong, Jianjun ^c   Liao, Lin ^d   Zhang, Weiwei ^e   Liu, Fupeng ^e,f  

^a Intensive Care Unit   (China)

^b Department of Medicine   (China)

^c SHANDONG UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF FREIBURG   (Germany)

^f Tengzhou Central People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; PLACEBO;

CANCER INCIDENCE; CANCER RISK; DRUG EFFECT; DRUG SAFETY; HUMAN; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84961174431     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-016-0389-8     Document Type: Review

References (51)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.
2. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173–81.
3. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77–88.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.
5. Holst JJ, Deacon CF, Vilsboll T, et al. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161–8.
6. Nauck MA, Vilsboll T, Gallwitz B, et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32(Suppl 2):S223–31.
7. Drucker DJ, Buse JB, Taylor Kendall DM, et al. Duration-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study. Lancet. 2008;372(9645):1240–50. doi:10.1016/S0140-6736(08)61206-4.
8. Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47. doi:10.1016/S0140-6736(09)60659-0.
9. Liu FP, Dong JJ, Yang Q, et al. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis. J Diabetes. 2015;7:322–8.
10. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981–8.
11. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–4.
12. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, an insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–46.
13. Bydureon package insert. http://www.azpicentral.com/bydureon/pi_bydureon.pdf#page=1. Accessed 23 Apr 2015.
14. Tanzeum package insert. https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF. Accessed 3 May 2015.
15. Trulicity package insert. http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed 3 May 2015.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
17. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
18. GlaxoSmithKline. Safety and efficacy study of albiglutide in type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT00849017?term=NCT00849017&rank=1. Accessed 25 Oct 2015.
19. GlaxoSmithKline. A study of the efficacy and safety of albiglutide in subjects with type 2 diabetes with renal impairment. https://clinicaltrials.gov/ct2/show/NCT01098539?term=01098539&rank=1. Accessed 25 Oct 2015.
20. GlaxoSmithKline. A monotherapy study to evaluate the efficacy and safety of 2 dose levels of albiglutide in Japanese subjects with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT01733758?term=01733758&rank=1. Accessed 25 Oct 2015.
21. GlaxoSmithKline. A study to determine the efficacy and safety of albiglutide as compared with liraglutide. https://clinicaltrials.gov/ct2/show/NCT01128894?term=01128894&rank=1. Accessed 25 Oct 2015.
22. GlaxoSmithKline. A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT00838916?term=00838916&rank=1. Accessed 25 Oct 2015.
23. GlaxoSmithKline. A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT00839527?term=00839527&rank=1. Accessed 25 Oct 2015.
24. GlaxoSmithKline. Efficacy and safety of albiglutide in treatment of type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT00838903?term=00838903&rank=1. Accessed 25 Oct 2015.
25. GlaxoSmithKline. A study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine. https://clinicaltrials.gov/ct2/show/NCT00976391?term=00976391&rank=1. Accessed 25 Oct 2015.
26. GlaxoSmithKline. Safety and efficacy of albiglutide in type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT00849056?term=00849056&rank=1. Accessed 25 Oct 2015.
27. AstraZeneca. Effects of exenatide long-acting release on glucose control and safety in subjects with type 2 diabetes mellitus (DURATION-1). https://clinicaltrials.gov/ct2/show/NCT00308139?term=00308139&rank=1. Accessed 25 Oct 2015.
28. AstraZeneca. Comparison study of the glycemic effects, safety, and tolerability of exenatide once weekly suspension to sitagliptin and placebo in subjects with type 2 diabetes mellitus (DURATION-NEO-2). https://clinicaltrials.gov/ct2/show/NCT01652729?term=NCT01652729&rank=1. Accessed 25 Oct 2015.
29. AstraZeneca. Safety and efficacy of exenatide once weekly injection versus metformin, dipeptidyl peptidase-4 inhibitor, or thiazolidinedione as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4). https://clinicaltrials.gov/ct2/show/NCT00676338?term=00676338&rank=1. Accessed 25 Oct 2015.
30. AstraZeneca. Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01029886?term=01029886&rank=1. Accessed 25 Oct 2015.
31. AstraZeneca. Efficacy of once-weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01003184?term=01003184&rank=1. Accessed 25 Oct 2015.
32. AstraZeneca. A study to compare the glycemic effects, safety, and tolerability of exenatide once weekly to those of sitagliptin and pioglitazone,in subjects with type 2 diabetes treated with metformin (DURATION-2). https://clinicaltrials.gov/ct2/show/NCT00637273?term=00637273&rank=1. Accessed 25 Oct 2015.
33. Eli Lilly and Company. A study comparing the effect of dulaglutide with liraglutide in type 2 diabetes (AWARD-6). https://clinicaltrials.gov/ct2/show/NCT01624259?term=01624259&rank=1. Accessed 25 Oct 2015.
34. Eli Lilly and Company. A study of dulaglutide in Japanese participants with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT01584232?term=01584232&rank=1. Accessed 25 Oct 2015.
35. Eli Lilly and Company. A study of LY2189265 compared to sitagliptin in participants with type 2 diabetes mellitus on metformin. https://clinicaltrials.gov/ct2/show/NCT00734474?term=00734474&rank=1. Accessed 25 Oct 2015.
36. Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-2). https://clinicaltrials.gov/ct2/show/NCT01075282?term=01075282&rank=1. Accessed 25 Oct 2015.
37. Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-4). https://clinicaltrials.gov/ct2/show/NCT01191268?term=01191268&rank=1. Accessed 25 Oct 2015.
38. Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-3). https://clinicaltrials.gov/ct2/show/NCT01126580?term=01126580&rank=1. Accessed 25 Oct 2015.
39. Eli Lilly and Company. A study of LY2189265 in Japanese participants with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT01558271?term=01558271&rank=1. Accessed 25 Oct 2015.
40. Eli Lilly and Company. A study of the effect of LY2189265 on blood pressure and heart rate in type 2 diabetes. https://clinicaltrials.gov/ct2/show/NCT01149421?term=01149421&rank=1. Accessed 25 Oct 2015.
41. Eli Lilly and Company. A study of dose titration of LY2189265 in overweight participants with type 2 diabetes mellitus (EGO). https://clinicaltrials.gov/ct2/show/NCT00630825?term=00630825&rank=1. Accessed 25 Oct 2015.
42. Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-1). https://clinicaltrials.gov/ct2/show/NCT01064687?term=01064687&rank=1. Accessed 25 Oct 2015.
43. Eli Lilly and Company. A study comparing the effects and safety of dulaglutide with insulin glargine in type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT01648582?term=NCT01648582&rank=1. Accessed 25 Oct 2015.
44. U.S. Department of Food and Drug Administration. Adverse Event Reporting System [Internet], 2011. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed 31 Mar 2014.
45. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–6.
46. Butler PC, Matveyenko AV, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia. 2010;53:1–6.
47. Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D)mouse model. Diabetes. 2012;61:1250–62.
48. Bjerre Knudsen L, Madsen LW, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–86.
49. Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891–905.
50. Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152(9):3362–72.
51. Ligumsky H, Wolf I, Israeli S, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012;132:449–61.